Aerie Pharmaceuticals (NASDAQ:AERI) had its price objective hoisted by Stifel Nicolaus from $80.00 to $87.00 in a research report report published on Tuesday morning, The Fly reports. They currently have a buy rating on the stock.

A number of other research analysts have also weighed in on AERI. BidaskClub lowered Aerie Pharmaceuticals from a sell rating to a strong sell rating in a report on Saturday, September 8th. ValuEngine lowered Aerie Pharmaceuticals from a strong-buy rating to a buy rating in a report on Tuesday, August 28th. Canaccord Genuity reaffirmed a buy rating and set a $86.00 price objective on shares of Aerie Pharmaceuticals in a report on Friday, August 10th. Cowen upped their price objective on Aerie Pharmaceuticals from $100.00 to $105.00 and gave the stock a buy rating in a report on Thursday, August 9th. Finally, HC Wainwright set a $78.00 price objective on Aerie Pharmaceuticals and gave the stock a buy rating in a report on Thursday, August 9th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the stock. Aerie Pharmaceuticals has an average rating of Buy and a consensus price target of $83.10.

NASDAQ:AERI opened at $59.15 on Tuesday. The company has a quick ratio of 10.07, a current ratio of 10.27 and a debt-to-equity ratio of 0.64. Aerie Pharmaceuticals has a 12-month low of $47.05 and a 12-month high of $74.75.

Aerie Pharmaceuticals (NASDAQ:AERI) last released its earnings results on Wednesday, August 8th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.98) by ($0.16). The firm had revenue of $2.42 million during the quarter, compared to analyst estimates of $1.16 million. sell-side analysts predict that Aerie Pharmaceuticals will post -4.51 earnings per share for the current fiscal year.

In other Aerie Pharmaceuticals news, CFO Richard J. Rubino sold 34,512 shares of the business’s stock in a transaction on Thursday, September 13th. The stock was sold at an average price of $60.17, for a total transaction of $2,076,587.04. Following the sale, the chief financial officer now directly owns 383,738 shares in the company, valued at $23,089,515.46. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Casey C. Kopczynski sold 11,000 shares of the business’s stock in a transaction on Wednesday, August 1st. The stock was sold at an average price of $68.30, for a total value of $751,300.00. Following the sale, the insider now owns 163,307 shares in the company, valued at $11,153,868.10. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 257,512 shares of company stock worth $15,670,247. 10.53% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Amalgamated Bank lifted its position in shares of Aerie Pharmaceuticals by 20.0% in the second quarter. Amalgamated Bank now owns 5,441 shares of the company’s stock valued at $368,000 after acquiring an additional 906 shares in the last quarter. UBS Group AG lifted its position in shares of Aerie Pharmaceuticals by 142.3% in the first quarter. UBS Group AG now owns 9,409 shares of the company’s stock valued at $511,000 after acquiring an additional 5,526 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in shares of Aerie Pharmaceuticals by 10.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 182,345 shares of the company’s stock valued at $9,893,000 after acquiring an additional 17,740 shares in the last quarter. C WorldWide Group Holding A S lifted its position in shares of Aerie Pharmaceuticals by 52.4% in the second quarter. C WorldWide Group Holding A S now owns 110,838 shares of the company’s stock valued at $7,487,000 after acquiring an additional 38,099 shares in the last quarter. Finally, Swiss National Bank lifted its position in shares of Aerie Pharmaceuticals by 9.6% in the second quarter. Swiss National Bank now owns 59,100 shares of the company’s stock valued at $3,992,000 after acquiring an additional 5,200 shares in the last quarter. Institutional investors own 96.00% of the company’s stock.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Further Reading: What is Compound Annual Growth Rate (CAGR)?

The Fly

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.